The Weekly Weight-Loss Pill: A New Hope in Obesity Treatment?

LONDON & SAN FRANCISCO – February 24, 2026 – The race to develop more patient-friendly obesity treatments has reached a new milestone. Verdiva Bio, a clinical-stage biopharmaceutical company, announced today it has completed enrollment for a pivotal Phase 2b study of its investigational drug, VRB-101. The drug is a potential first-in-class, once-weekly oral GLP-1 peptide analog, a combination of words that could signal a paradigm shift in how millions manage their weight. As the world grapples with a growing obesity crisis, the prospect of a simple, weekly pill that delivers the power of blockbuster injectable drugs represents a significant leap forward.

The trial, dubbed EVOLVE-2, has enrolled over 200 individuals with obesity or overweight across the United States. Its completion marks a critical step for Verdiva Bio as it seeks to challenge the market titans and offer a new level of convenience in a field accustomed to daily pills and injections. With topline data expected by the end of 2026, all eyes are on this small but ambitious company and its potentially transformative therapy.

The Quest for a Weekly Pill in a Crowded Market

The market for GLP-1 agonists has exploded in recent years, turning drugs like Novo Nordisk's injectable Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide) into household names and multi-billion dollar products. Their profound effectiveness in promoting weight loss and improving metabolic health has been revolutionary. However, the reliance on injections remains a barrier for many, due to needle phobia, inconvenience, or discomfort.

To address this, both pharma giants have pushed into the oral space. Novo Nordisk's once-daily Wegovy pill, approved in late 2025, and Eli Lilly's once-daily orforglipron (Foundayo), approved in April 2026, have already begun to capture a significant share of the market. These pills eliminated the need for needles but introduced the new routine of a daily dose, with some, like oral Wegovy, requiring specific fasting conditions for proper absorption.

This is where Verdiva Bio hopes to carve out its niche. VRB-101’s promise lies in its once-weekly dosing schedule. If successful, it would combine the efficacy of powerful GLP-1 peptides with the unparalleled convenience of a weekly pill, a potential best-of-both-worlds scenario for patients. This positions VRB-101 not just as an alternative, but as a potential evolution in treatment, dramatically simplifying long-term therapy adherence for a chronic disease. The company's 'first-in-class' claim hinges on this specific combination: a peptide-based GLP-1 delivered orally, once a week.

Unlocking Oral Peptides: The Science Behind VRB-101

For decades, delivering large-molecule drugs like peptides orally was considered a pharmaceutical holy grail. These complex molecules are typically destroyed by the harsh, acidic environment of the stomach and digestive enzymes long before they can be absorbed into the bloodstream. This is why GLP-1 therapies have historically been injectable.

Verdiva Bio's approach, like that of its competitors, relies on a sophisticated proprietary oral delivery technology. While Novo Nordisk uses a carrier molecule called SNAC to protect its oral semaglutide, Verdiva Bio leverages a technology in-licensed from Sciwind Biosciences, which developed the core compound, ecnoglutide. This technology is designed to shield the peptide from degradation and facilitate its absorption into the body, enabling a systemic effect from a simple pill. The goal is to achieve drug exposure levels in the blood that are comparable to, or even better than, the current gold-standard weekly injections.

Early data is promising. Pharmacokinetic (PK) modeling from a Phase 1 study, presented at the American Diabetes Association's 85th Scientific Sessions, suggested that oral VRB-101 could indeed achieve drug levels similar to or higher than weekly injectable semaglutide. Furthermore, in an earlier trial run by Sciwind, a daily version of oral ecnoglutide led to a mean body weight reduction of 6.8% in just six weeks, providing strong initial evidence of the compound's potency.

A 'Biased' Approach to Better Outcomes

Beyond its innovative delivery method, VRB-101's design incorporates another layer of advanced science: it is a 'cAMP-biased' agonist. This term refers to how the drug interacts with the GLP-1 receptor on a cellular level. When a traditional GLP-1 drug binds to its receptor, it triggers multiple signaling pathways. One pathway, mediated by a molecule called cyclic AMP (cAMP), is largely responsible for the desired therapeutic effects: appetite suppression, improved insulin secretion, and weight loss. Another pathway, involving a protein called β-arrestin, is thought to contribute to receptor desensitization (making the drug less effective over time) and some of the common gastrointestinal side effects like nausea and vomiting.

A cAMP-biased agonist like ecnoglutide is engineered to preferentially activate the beneficial cAMP pathway while minimizing engagement with the β-arrestin pathway. In theory, this could lead to a more potent therapeutic effect with a better side-effect profile. This concept of 'biased agonism' is not just theoretical; it is believed to contribute to the powerful effects of highly successful drugs like tirzepatide. By fine-tuning the drug’s molecular action, Verdiva Bio aims to deliver not just a more convenient therapy, but a potentially more effective and tolerable one.

What's Next for Verdiva Bio and EVOLVE-2

The now fully-enrolled EVOLVE-2 study is a randomized, double-blind, placebo-controlled trial—the gold standard for clinical research. Its primary goal is to measure the mean percentage of body weight change from baseline after 20 weeks of once-weekly oral dosing. The trial's design, with five different active dose arms, will be crucial in identifying the optimal starting and maintenance doses for potential future Phase 3 trials, which Verdiva Bio hopes to initiate in 2027, assuming positive results.

“Obesity is a multifactorial chronic disease with important health-related complications requiring long-term therapy,” stated Dr. Mohamed Eid, CMO at Verdiva Bio, in the company's press release. He noted that previous studies and PK modeling support a promising clinical profile for VRB-101, adding that it “appears to have the potential to become a first-in-class once-weekly oral GLP-1 analog for people living with obesity or overweight.”

Verdiva Bio's ambitions don't stop with VRB-101. The company is also developing a portfolio of other molecules, including amylin agonists, which could be used in combination therapies to achieve even healthier and more significant weight loss. For now, however, the focus remains squarely on the data to come. As the EVOLVE-2 participants complete their 20-week journey, the medical and investment communities will be waiting with keen anticipation for the results at the end of 2026, which could validate the promise of a once-a-week weight-loss pill and position a new, formidable player on the global stage.